AHB

AHB is a clinical-stage biotechnology company dedicated to developing innovative multi-specific antibody therapies for the treatment of chronic infectious diseases and cancer. The company leverages its proprietary platform to engineer antibodies that can simultaneously target multiple epitopes or pathways, aiming for functional cures in conditions like Chronic Hepatitis B. Its lead program, AHB-001, is a first-in-class multi-specific antibody designed to clear Hepatitis B virus surface antigens and stimulate host immune responses. AHB is headquartered in Beijing and has established a robust pipeline of candidates targeting high-unmet-need areas in immunology and oncology. The company is supported by a syndicate of leading life science investors and maintains a global perspective on clinical development.